Summary Basis of Decision (SBD) for Pomalyst

Health Canada has issued a Notice of Compliance to Celgene Inc. for the drug product Pomalyst. Based on Health Canada's review, the benefit/risk profile of Pomalyst is considered favourable, in combination with dexamethasone (Pomalyst+LD-dex), for patients with multiple myeloma for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen. Read more here.